Viral Filtration: A Review of
Current and Future Practices in Bioprocessing
AUTHOR NAMES: Sarah A Johnson1; Shuang
Chen2; Glen Bolton3; Qi
Chen4; Scott Lute1; John
Fisher4; Kurt Brorson5
AUTHOR ADDRESSES:
- Office of Biotechnology Products, CDER, FDA 10903 New Hampshire Ave.,
Silver Spring Maryland
- NGM Biopharmaceuticals Inc., South San Francisco CA
- Amgen Inc., Cambridge MA
- Genentech Inc. South San Francisco CA
- Parexel International., Newton MA
AUTHOR EMAIL ADDRESS: ’Johnson, Sarah (CDER)’
<Sarah.Johnson1@fda.hhs.gov>; Shuang Chen
<schen@ngmbio.com>; Bolton, Glen
<gbolton@amgen.com>; Qi Chen
<chen.qi@gene.com>; Lute, Scott
<Scott.Lute@fda.hhs.gov>; John Fisher
fisher.john@gene.com; Kurt Brorson
<kurt.brorson@parexel.com>
CORRESPONDING AUTHOR: Kurt Brorson
<kurt.brorson@parexel.com>